Early Outcomes of the First 200 US Patients Treated with Impella 5.5: A Novel Temporary Left Ventricular Assist Device.
Nicholas RayMark AndersonGeorge BatsidesMasahiro OnoScott SilvestryDavid A D'AlessandroMasaki FunamotoElias A ZiasAnthony LemaireEdward SoltesePublished in: Innovations (Philadelphia, Pa.) (2021)
In the first 200 US patients treated with the Impella 5.5, we observed overall survival to explant of 74%. Survival outcomes were improved compared to historic rates observed with cardiogenic shock, particularly PCCS. Prospective studies assessing comparative performance of this device to conventional strategies are warranted in future.